公开(公告)号：US11518726B2

公开(公告)日：2022-12-06

申请号：US16754206

申请日：2018-10-10

申请人： Eastman Chemical Company

发明人： Yue Rachel Hu ,  Robert Thomas Hembre ,  Gerald Charles Tustin ,  Zhufang Liu ,  Steven J. Adams

IPC分类号： C07C29/60 ,  C07C45/50 ,  C07C51/16 ,  C07C67/36 ,  C07C209/16 ,  C07C231/02 ,  C07C263/10 ,  C07C29/48 ,  C07C69/013 ,  C07C51/12 ,  C07C61/13 ,  C07C31/27 ,  C07C211/19 ,  C07C215/20 ,  C07C213/02

摘要： Provided is a process for the preparation of certain 1,4-bicyclo[2.2.2]octane derivatives. The new synthetic procedure involves treating 1,4-dimethylene cyclohexane with an oxidizing agent in the presence of a transition metal catalyst to afford an oxo-substituted bicyclo[2.2.2]octane species. This intermediate structure can then be further derivatized. The processes of this disclosure thus affords a novel and simplified means for the commercial production of a wide variety of bicyclo[2.2.2]octane derivatives.

公开(公告)号：US20220363626A1

公开(公告)日：2022-11-17

申请号：US17853069

申请日：2022-06-29

申请人： CORSAIR PHARMA, INC.

发明人： Xiaoming ZHANG ,  Meenakshi S. VENKATRAMAN ,  Cyrus K. BECKER

IPC分类号： C07C69/734 ,  C07C69/732 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/96 ,  C07D303/48 ,  A61K9/00 ,  A61K9/70 ,  A61K31/216 ,  A61K45/06

摘要： The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

公开(公告)号：US11407707B2

公开(公告)日：2022-08-09

申请号：US16936256

申请日：2020-07-22

申请人： CORSAIR PHARMA, INC.

发明人： Xiaoming Zhang ,  Meenakshi S. Venkatraman ,  Cyrus K. Becker

IPC分类号： C07C69/734 ,  C07C69/732 ,  A61K31/216 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/96 ,  C07D303/48 ,  A61K9/00 ,  A61K9/70 ,  A61K45/06

摘要： The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

公开(公告)号：US11370743B2

公开(公告)日：2022-06-28

申请号：US16604665

申请日：2018-05-10

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Paul A. Wender ,  Katherine N. Keenan ,  Nancy Lynn Benner ,  Jack Leider Sloane ,  Xiaoyu Zang

IPC分类号： C07C69/013 ,  A61P31/18 ,  C07C69/78 ,  A61K9/00

摘要： Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

公开(公告)号：US10759733B2

公开(公告)日：2020-09-01

申请号：US16580828

申请日：2019-09-24

申请人： CORSAIR PHARMA, INC.

发明人： Xiaoming Zhang ,  Meenakshi S. Venkatraman ,  Cyrus K. Becker

IPC分类号： C07C69/734 ,  C07C69/732 ,  A61K31/216 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/96 ,  C07D303/48 ,  A61K9/00 ,  A61K9/70 ,  A61K45/06

摘要： The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

公开(公告)号：US10053414B2

公开(公告)日：2018-08-21

申请号：US15617243

申请日：2017-06-08

申请人： CORSAIR PHARMA, INC.

发明人： Xiaoming Zhang ,  Meenakshi S. Venkatraman ,  Cyrus K. Becker

IPC分类号： C07C69/734 ,  C07C69/732 ,  A61K31/216 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/96 ,  C07D303/48 ,  A61K9/00 ,  A61K9/70 ,  A61K45/06 ,  C07C69/013

CPC分类号： C07C69/734 ,  A61K9/0014 ,  A61K9/7023 ,  A61K31/216 ,  A61K45/06 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/732 ,  C07C69/96 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2603/14 ,  C07D303/48

摘要： The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

公开(公告)号：US20180155616A1

公开(公告)日：2018-06-07

申请号：US15735013

申请日：2016-05-13

申请人： Merck Patent GmbH

发明人： Gaëlle BÉALLE ,  Christoph LEONHARD ,  Hsin-Rong TSENG ,  Irina MARTYNOVA ,  Aurélie LUDEMANN

IPC分类号： C09K11/06 ,  H01L51/00 ,  C07C69/013 ,  C07C69/22

摘要： The present invention relates to formulations for the preparation of organic electronic devices (OLEDs) which comprise at least one specific ester solvent containing a non aromatic cycle and at least one organic functional material selected from organic conductors, organic semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organic light-absorbent compounds, organic light-sensitive compounds, organic photosensitisation agents and other organic photoactive compounds, selected from organometallic complexes of transition metals, rare earths, lanthanides and actinides.

公开(公告)号：US20170369418A1

公开(公告)日：2017-12-28

申请号：US15541038

申请日：2016-02-04

申请人： JNC CORPORATION ,  JNC PETROCHEMICAL CORPORATION

发明人： Hiroyuki TANAKA ,  Masakazu YANO ,  Fumitaka KONDOU ,  Kazuhiro OGITA

IPC分类号： C07C69/732 ,  C07C69/003 ,  C07C69/013 ,  C07C69/017 ,  C07C229/12 ,  C09K19/06 ,  C09K19/36 ,  C09K19/30 ,  C09K19/12 ,  G02F1/1337 ,  C07J9/00 ,  G02F1/1362 ,  C07C2601/14

CPC分类号： C07C69/732 ,  C07C69/003 ,  C07C69/013 ,  C07C69/017 ,  C07C229/08 ,  C07C229/12 ,  C07C229/30 ,  C07C321/10 ,  C07C2601/14 ,  C07D213/55 ,  C07D239/26 ,  C07D295/145 ,  C07D309/06 ,  C07D319/06 ,  C07F5/02 ,  C07F7/18 ,  C07J9/00 ,  C09K19/04 ,  C09K19/062 ,  C09K19/063 ,  C09K19/12 ,  C09K19/126 ,  C09K19/18 ,  C09K19/3003 ,  C09K19/32 ,  C09K19/322 ,  C09K19/34 ,  C09K19/3402 ,  C09K19/3483 ,  C09K19/36 ,  C09K19/42 ,  C09K19/54 ,  C09K2019/0444 ,  C09K2019/0448 ,  C09K2019/122 ,  C09K2019/123 ,  C09K2019/181 ,  C09K2019/3004 ,  C09K2019/3006 ,  C09K2019/3009 ,  C09K2019/301 ,  C09K2019/3015 ,  C09K2019/3016 ,  C09K2019/3019 ,  C09K2019/3025 ,  C09K2019/303 ,  C09K2019/3077 ,  C09K2019/3422 ,  G02F1/1337 ,  G02F1/133788 ,  G02F1/1362

摘要： Provided is a polar compound having high chemical stability, high capability of aligning liquid crystal molecules, high solubility in a liquid crystal composition, and a large voltage holding ratio when used in a liquid crystal display device. The compound is represented by formula (1): in which, for example, R1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp1 is a single bond or alkylene having 1 to 10 carbons; M1 and M2 are hydrogen; and R2 is a group represented by formulas (1a) to (1c): in which, Sp2 and Spa are a single bond or alkylene having 1 to 10 carbons; S1 is >CH—; S2 is >C

公开(公告)号：US09701616B2

公开(公告)日：2017-07-11

申请号：US15178637

申请日：2016-06-10

申请人： CORSAIR PHARMA, INC.

发明人： Xiaoming Zhang ,  Meenakshi S. Venkatraman ,  Cyrus K. Becker

IPC分类号： C07C69/732 ,  A61K31/216 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/96 ,  C07D303/48 ,  A61K9/00 ,  A61K9/70 ,  A61K45/06

CPC分类号： C07C69/734 ,  A61K9/0014 ,  A61K9/7023 ,  A61K31/216 ,  A61K45/06 ,  C07C69/013 ,  C07C69/26 ,  C07C69/675 ,  C07C69/708 ,  C07C69/712 ,  C07C69/732 ,  C07C69/96 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2603/14 ,  C07D303/48

摘要： The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

公开(公告)号：US09603825B2

公开(公告)日：2017-03-28

申请号：US14824688

申请日：2015-08-12

申请人： BIOSUCCESS BIOTECH CO., LTD.

发明人： Zheng Tao Han ,  Richard L. Chang

IPC分类号： A61K31/215 ,  A61K31/573 ,  A61K31/60 ,  A61K31/23 ,  A61K31/55 ,  A61K31/225 ,  A61K31/606 ,  A61K45/06 ,  C07C69/33 ,  C07C69/013

CPC分类号： A61K31/23 ,  A61K31/225 ,  A61K31/55 ,  A61K31/573 ,  A61K31/60 ,  A61K31/606 ,  A61K45/06 ,  C07C69/013 ,  C07C69/33 ,  C07C2603/40 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/492

摘要： Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects.